1B. Isomaa, P. Almgren, T. Tuomi et al. Cardiovascular morbidity and mortality associated with the metabolie syndrome. Diabetes Care ,2001,24:683-689.
2H. M. Lakka, D. E. Laaksonen,T. A. Lakka et al. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA ,2002,288:2709-2716.
3P. M. Ridker,J. E. Buring,N. R. Cook and N. Rifai,C-reactive protein,the metabolic syndrome, and risk of incident cardiovascular events : an 8-year follow-up of 14 719 initially healthy American women. Circulation ,2003,107:391-397.
4A. O. Rantala, H. Kauma, M. Lilja et al. Prevalence of the metabolic syndrome in drug-treated hypertensive patients and control subjects. J Intern Med, 1999,245 : 163-174.
5Gorter PM, Olijhoek JK, Graaf Y, et al. Prevalence of the metabolic syndrome in patients with coronary heart disease, cerebrovascular disease,peripheral arterial disease or abdominal aortic aneurysm. Atherosclerosis ,2004,173 : 361-367.
6Yaffe K, Knanya A,Lindquist K, et al. The Metabolic Syndrome, Inflammation, and Risk of Cognitive Decline. JAMA ,2004,292:2237-2242.
7de Ferranti ST, Gauvrcau K, Ludwig DS, et al. Prevalence of the Metabolic Syndrome in American Adolescents. Circulation ,2004,110:2494-2497.
8Haverate F, Thompson SG, Pyke SD, et al. Production of C reaction pro-tein and risk of coronary events in stable and unstable angina: European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. Lancet, 1997,349:462 -466.
9Koenig W, Khuseyinova N, Lowel H, et el. Lipoprotein-assoeiated phospholipase A2 adds to risk prediction of incident coronary events by Creactive protein in apparently healthy middle-e.ged men from the general population: results from the 14-year follow-up of a large cohort fromsouthern Germany. Circulation ,2004,110 : 1903-1908.
10Akbiyik F, Ray DM, Gettings KF, et al. Human bone marrow megakaryocytes and platelets express PPARgamma, and PPARgamma agonists blunt platelet release of CD40 ligand and thromboxanes.Blood ,2004,104 : 1361-1368.
